911481-41-9

Basic information

• Product Name: MOC-Norleucine
• Synonyms: MOC-Norleucine;MOC-Nle-OH;(S)-2-((Methoxycarbonyl)aMino)hexanoic acid
• CAS NO: 911481-41-9
• Molecular Formula: C8H15NO4
• Molecular Weight: 189.209
• Mol File: 911481-41-9.mol

Chemical Properties

• Boiling Point: 336.1±25.0 °C(Predicted)
• Appearance: /
• Density: 1.126±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.45±0.21(Predicted)
• CAS DataBase Reference: MOC-Norleucine(CAS DataBase Reference)
• NIST Chemistry Reference: MOC-Norleucine(911481-41-9)
• EPA Substance Registry System: MOC-Norleucine(911481-41-9)

Safety Data

• Hazardous Substances Data: 911481-41-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
MOC-Norleucine is used as a building block in solid-phase peptide synthesis for the development of custom peptides with specific modifications or functionalities. Its incorporation allows for the creation of diverse peptides with potential applications in drug discovery and therapeutics.
Used in Research Applications:
In the field of peptide chemistry, MOC-Norleucine is used as a versatile component in the synthesis of specialized peptides. Its modified side chain enables the design of peptides with unique properties, facilitating research in areas such as protein structure, function, and interaction studies.

Upstream product

• 616-06-8 2-amino-hexanoic acid 
• 79-22-1 methyl chloroformate 
• 327-57-1 L-Norleucine 
• 327-56-0 D-norleucine 

Relevant articles and documents

A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus

A medicinal chemistry program based on the small-molecule HCV NS5A inhibitor daclatasvir has led to the discovery of dimeric phenylthiazole compound 8, a novel and potent HCV NS5A inhibitor. The subsequent SAR studies and optimization revealed that the cycloalkyl amide derivatives 27a-29a exhibited superior potency against GT1b with GT1b EC50 values at picomolar concentration. Interestingly, high diastereospecificity for HCV inhibition was observed in this class with the (1R,2S,1′R,2′S) diastereomer displaying the highest GT1b inhibitory activity. The best inhibitor 27a was found to be 3-fold more potent (GT1b EC50 = 0.003 nM) than daclatasvir (GT1b EC50 = 0.009 nM) against GT1b, and no detectable in vitro cytotoxicity was observed (CC50 > 50 μM). Pharmacokinetic studies demonstrated that compound 27a had an excellent pharmacokinetic profiles with a superior oral exposure and desired bioavailability after oral administration in both rats and dogs, and therefore it was selected as a developmental candidate for the treatment of HCV infection.

Synthesis, antidepressant activity, and toxicity of the erythro/threo racemates and optical isomers of 2-(4-benzylpiperazin-1-yl)-1-(5-chloro-6-methoxynaphthalen-2-yl)hexan-1-ol

The erythro/threo racemates and their four optical isomers of 2-(4-benzylpiperazin-1-yl)-1-(5-chloro-6-methoxynaphthalen-2-yl)hexan-1-ol were synthesized and evaluated for their antidepressant activity, toxicity, and pharmacokinetics as novel triple multi